Technical Analysis for BIVI - BioVie Inc.

Grade Last Price % Change Price Change
F 14.78 3.00% 0.43
BIVI closed up 3.0 percent on Friday, March 5, 2021, on 1.79 times normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical BIVI trend table...

Date Alert Name Type % Chg
Hammer Candlestick Bullish 0.00%
Lizard Bullish Bullish Day Trade Setup 0.00%
Doji - Bullish? Reversal 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 200 DMA Bearish 3.00%
Volume Surge Other 3.00%
Lower Bollinger Band Walk Weakness 3.00%
Older End-of-Day Signals for BIVI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BioVie Inc. Description

BioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of market exclusivity in the US for the designated use(s). It is being investigated as a potential new therapy for patients suffering from ascites, and future development opportunities include hepatorenal syndrome (HRS) and other life-threatening complications of advanced liver cirrhosis. The initial disease target for BIV201 therapy is ascites, which is a serious complication of advanced liver cirrhosis. The Company has completed a Phase 2 clinical trial protocol that is summarized on www.clinicaltrials.gov, trial identifier NCT04112199. The FDA has never approved any drug specifically for treating ascites, and the Company is not aware of any competing drugs in late-stage development for ascites. The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The Company has invented a patent-pending prefilled syringe that has been cleared for use in our upcoming Phase 2 trial subject to certain additional standard analytical tests. This novel BIV201 delivery system is expected to greatly simplify at-home patient treatment and improve patient compliance by enabling easy injection of the liquid concentrate into the IV bag connected to the infusion pump. Room temperature stability has been achieved for 9 months providing an important advantage because, to the best of the Company's knowledge, all other terlipressin products sold globally must be stored under refrigeration. The novel prefilled syringe format also avoids the manual mixing of minute (2 - 4 mg) quantities of terlipressin powder in saline solution, thereby reducing the possibility of dosing errors during reconstitution and improving sterility. BioVie has begun applying for global patent protection for this novel terlipressin delivery system. The Company has also received Orphan Drug designation for the treatment of hepatorenal syndrome (HRS) and has FDA Fast Track status.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Refrigeration FDA Hepatology Syringe Infusion Pump Drug Design Liver Digestive Diseases Orphan Drug Cirrhosis Hepatorenal Syndrome Ascites .Gov Sterility Treatment Of Hepatorenal Syndrome

Is BIVI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 46.0
52 Week Low 2.2
Average Volume 110,754
200-Day Moving Average 16.52
50-Day Moving Average 29.93
20-Day Moving Average 32.31
10-Day Moving Average 26.20
Average True Range 4.99
ADX 34.74
+DI 12.80
-DI 35.28
Chandelier Exit (Long, 3 ATRs ) 31.02
Chandelier Exit (Short, 3 ATRs ) 27.20
Upper Bollinger Band 48.31
Lower Bollinger Band 16.31
Percent B (%b) -0.05
BandWidth 99.05
MACD Line -3.57
MACD Signal Line -0.87
MACD Histogram -2.7019
Fundamentals Value
Market Cap 205.68 Million
Num Shares 13.9 Million
EPS -0.01
Price-to-Earnings (P/E) Ratio -1847.50
Price-to-Sales 0.00
Price-to-Book 8.43
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.56
Resistance 3 (R3) 19.24 17.32 18.76
Resistance 2 (R2) 17.32 16.11 17.48 18.50
Resistance 1 (R1) 16.05 15.36 15.10 16.37 18.23
Pivot Point 14.14 14.14 13.66 14.30 14.14
Support 1 (S1) 12.87 12.92 11.91 13.19 11.33
Support 2 (S2) 10.95 12.17 11.11 11.06
Support 3 (S3) 9.68 10.95 10.80
Support 4 (S4) 10.00